Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement, MSA, with Telix IsoTherapeutics Group. This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium Obisbemeda. Key highlights of the agreement: Focus on the production of key radionuclide intermediate aluminum perrhenate and the final processing of cGMP Re-186; Enables expanded, scalable, just-in-time manufacturing to support overall supply chain
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trial
- Plus Therapeutics to present FORESEE clinical trial summary
- Plus Therapeutics subsidiary to present data on CNSide CSF Assay Platform
- Plus Therapeutics Advances Radiotherapeutics in Q3 2024
- Plus Therapeutics reports Q3 EPS (37c), consensus (56c)